Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of small-cap biotech Delcath Systems (Nasdaq: DCTH ) popped more than 10% in intraday trading, as takeover rumors may have sparked investor excitement.
So what: The unconfirmed rumor has drug giant Bristol-Myers Squibb
Now what: Fools know never to jump into a stock on takeover speculation alone. But with Delcath recently validating positive trial results for its drug delivery system, as well as raising about $35 million in a secondary offering, the stock does sport some serious hidden potential. If Delcath gets its PHP system approved by mid-2011, like its CFO expects, today's speculation-fueled surge will likely be a drop in the bucket.
Update: On Friday, Oct. 8, Delcath shares moved an additional 14% in intraday trading on no new news.